TWI222863B - Synergistic pharmaceutical compositions comprising anthracycline derivatives and anticancer agents - Google Patents

Synergistic pharmaceutical compositions comprising anthracycline derivatives and anticancer agents Download PDF

Info

Publication number: TWI222863B
Authority: TW; Taiwan
Prior art keywords: cancer; application; item; drug; range
Prior art date: 1999-04-29

Application number

TW089106805A

Other languages

English (en)

Chinese (zh)

Inventor

Maria Cristina Geroni

Marina Ripamonti

Michele Caruso

Antonio Suarato

Original Assignee

Pharmacia & Upjohn Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-29

Filing date

2000-04-12

Publication date

2004-11-01

2000-04-12 Application filed by Pharmacia & Upjohn Spa filed Critical Pharmacia & Upjohn Spa

2004-11-01 Application granted granted Critical

2004-11-01 Publication of TWI222863B publication Critical patent/TWI222863B/zh

Links

239000002246 antineoplastic agent Substances 0.000 title claims abstract description 24
239000008194 pharmaceutical composition Substances 0.000 title claims description 17
230000002195 synergetic effect Effects 0.000 title claims description 4
229940045799 anthracyclines and related substance Drugs 0.000 title abstract description 4
239000003814 drug Substances 0.000 claims abstract description 16
208000014018 liver neoplasm Diseases 0.000 claims abstract description 15
229940079593 drug Drugs 0.000 claims abstract description 13
201000007270 liver cancer Diseases 0.000 claims abstract description 12
YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 claims description 22
206010028980 Neoplasm Diseases 0.000 claims description 21
JDLKFOPOAOFWQN-VIFPVBQESA-N Allicin Natural products C=CCS[S@](=O)CC=C JDLKFOPOAOFWQN-VIFPVBQESA-N 0.000 claims description 15
JDLKFOPOAOFWQN-UHFFFAOYSA-N allicin Chemical compound C=CCSS(=O)CC=C JDLKFOPOAOFWQN-UHFFFAOYSA-N 0.000 claims description 15
235000010081 allicin Nutrition 0.000 claims description 15
201000011510 cancer Diseases 0.000 claims description 13
150000001875 compounds Chemical class 0.000 claims description 13
239000003795 chemical substances by application Substances 0.000 claims description 10
210000004185 liver Anatomy 0.000 claims description 9
229940041181 antineoplastic drug Drugs 0.000 claims description 8
-1 chloroammonium molybdenum Chemical compound 0.000 claims description 8
239000000203 mixture Substances 0.000 claims description 8
241000234282 Allium Species 0.000 claims description 6
230000001093 anti-cancer Effects 0.000 claims description 6
235000002732 Allium cepa var. cepa Nutrition 0.000 claims description 4
229960004316 cisplatin Drugs 0.000 claims description 4
DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims description 4
239000000546 pharmaceutical excipient Substances 0.000 claims description 4
102000016736 Cyclin Human genes 0.000 claims description 3
108050006400 Cyclin Proteins 0.000 claims description 3
229960001756 oxaliplatin Drugs 0.000 claims description 3
DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims description 3
206010027476 Metastases Diseases 0.000 claims description 2
KMLCRELJHYKIIL-UHFFFAOYSA-N [1-(azanidylmethyl)cyclohexyl]methylazanide;platinum(2+);sulfuric acid Chemical compound [Pt+2].OS(O)(=O)=O.[NH-]CC1(C[NH-])CCCCC1 KMLCRELJHYKIIL-UHFFFAOYSA-N 0.000 claims description 2
239000003183 carcinogenic agent Substances 0.000 claims description 2
208000006990 cholangiocarcinoma Diseases 0.000 claims description 2
230000009401 metastasis Effects 0.000 claims description 2
230000007761 synergistic anti-cancer Effects 0.000 claims 2
OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
206010061336 Pelvic neoplasm Diseases 0.000 claims 1
DSVGQVZAZSZEEX-UHFFFAOYSA-N [C].[Pt] Chemical compound [C].[Pt] DSVGQVZAZSZEEX-UHFFFAOYSA-N 0.000 claims 1
DVQHYTBCTGYNNN-UHFFFAOYSA-N azane;cyclobutane-1,1-dicarboxylic acid;platinum Chemical compound N.N.[Pt].OC(=O)C1(C(O)=O)CCC1 DVQHYTBCTGYNNN-UHFFFAOYSA-N 0.000 claims 1
229910052799 carbon Inorganic materials 0.000 claims 1
206010073071 hepatocellular carcinoma Diseases 0.000 claims 1
231100000844 hepatocellular carcinoma Toxicity 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 23
238000002360 preparation method Methods 0.000 abstract description 16
238000011319 anticancer therapy Methods 0.000 abstract description 13
239000002256 antimetabolite Substances 0.000 abstract description 9
230000000340 anti-metabolite Effects 0.000 abstract description 8
229940100197 antimetabolite Drugs 0.000 abstract description 8
229940100198 alkylating agent Drugs 0.000 abstract description 6
239000002168 alkylating agent Substances 0.000 abstract description 6
230000002927 anti-mitotic effect Effects 0.000 abstract description 3
230000001394 metastastic effect Effects 0.000 abstract description 3
206010061289 metastatic neoplasm Diseases 0.000 abstract description 3
229940123780 DNA topoisomerase I inhibitor Drugs 0.000 abstract 1
229940124087 DNA topoisomerase II inhibitor Drugs 0.000 abstract 1
239000000365 Topoisomerase I Inhibitor Substances 0.000 abstract 1
239000000317 Topoisomerase II Inhibitor Substances 0.000 abstract 1
125000002757 morpholinyl group Chemical group 0.000 abstract 1
239000003112 inhibitor Substances 0.000 description 17
239000000126 substance Substances 0.000 description 16
102000004195 Isomerases Human genes 0.000 description 12
108090000769 Isomerases Proteins 0.000 description 12
238000000034 method Methods 0.000 description 10
BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 9
AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 8
150000003057 platinum Chemical class 0.000 description 8
239000003080 antimitotic agent Substances 0.000 description 7
230000000694 effects Effects 0.000 description 7
241000124008 Mammalia Species 0.000 description 6
241000282414 Homo sapiens Species 0.000 description 5
230000000259 anti-tumor effect Effects 0.000 description 5
208000032839 leukemia Diseases 0.000 description 5
241000282412 Homo Species 0.000 description 4
229960004679 doxorubicin Drugs 0.000 description 4
239000003394 isomerase inhibitor Substances 0.000 description 4
CTMCWCONSULRHO-UHQPFXKFSA-N nemorubicin Chemical compound C1CO[C@H](OC)CN1[C@@H]1[C@H](O)[C@H](C)O[C@@H](O[C@@H]2C3=C(O)C=4C(=O)C5=C(OC)C=CC=C5C(=O)C=4C(O)=C3C[C@](O)(C2)C(=O)CO)C1 CTMCWCONSULRHO-UHQPFXKFSA-N 0.000 description 4
229910052697 platinum Inorganic materials 0.000 description 4
230000000699 topical effect Effects 0.000 description 4
210000004881 tumor cell Anatomy 0.000 description 4
206010019695 Hepatic neoplasm Diseases 0.000 description 3
241001529936 Murinae Species 0.000 description 3
239000004480 active ingredient Substances 0.000 description 3
150000001335 aliphatic alkanes Chemical class 0.000 description 3
230000000719 anti-leukaemic effect Effects 0.000 description 3
210000004027 cell Anatomy 0.000 description 3
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 3
229960005091 chloramphenicol Drugs 0.000 description 3
201000010099 disease Diseases 0.000 description 3
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 description 3
238000002513 implantation Methods 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
239000004615 ingredient Substances 0.000 description 3
239000012907 medicinal substance Substances 0.000 description 3
238000002560 therapeutic procedure Methods 0.000 description 3
HAWSQZCWOQZXHI-FQEVSTJZSA-N 10-Hydroxycamptothecin Chemical compound C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-FQEVSTJZSA-N 0.000 description 2
101710095468 Cyclase Proteins 0.000 description 2
241001465754 Metazoa Species 0.000 description 2
241000699670 Mus sp. Species 0.000 description 2
NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
230000009471 action Effects 0.000 description 2
210000000481 breast Anatomy 0.000 description 2
239000000969 carrier Substances 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
230000002708 enhancing effect Effects 0.000 description 2
238000009472 formulation Methods 0.000 description 2
239000007943 implant Substances 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
239000007924 injection Substances 0.000 description 2
238000002347 injection Methods 0.000 description 2
210000003734 kidney Anatomy 0.000 description 2
210000004072 lung Anatomy 0.000 description 2
SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 description 2
230000001613 neoplastic effect Effects 0.000 description 2
231100000252 nontoxic Toxicity 0.000 description 2
230000003000 nontoxic effect Effects 0.000 description 2
210000002307 prostate Anatomy 0.000 description 2
235000000346 sugar Nutrition 0.000 description 2
230000004083 survival effect Effects 0.000 description 2
239000000725 suspension Substances 0.000 description 2
238000012360 testing method Methods 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
FDKXTQMXEQVLRF-ZHACJKMWSA-N (E)-dacarbazine Chemical compound CN(C)\N=N\c1[nH]cnc1C(N)=O FDKXTQMXEQVLRF-ZHACJKMWSA-N 0.000 description 1
UHDGCWIWMRVCDJ-UHFFFAOYSA-N 1-beta-D-Xylofuranosyl-NH-Cytosine Natural products O=C1N=C(N)C=CN1C1C(O)C(O)C(CO)O1 UHDGCWIWMRVCDJ-UHFFFAOYSA-N 0.000 description 1
AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
VSHBABSXFHFTJN-UHFFFAOYSA-N 4-methoxymorpholine Chemical compound CON1CCOCC1 VSHBABSXFHFTJN-UHFFFAOYSA-N 0.000 description 1
235000003092 Artemisia dracunculus Nutrition 0.000 description 1
240000001851 Artemisia dracunculus Species 0.000 description 1
206010004593 Bile duct cancer Diseases 0.000 description 1
HAWSQZCWOQZXHI-UHFFFAOYSA-N CPT-OH Natural products C1=C(O)C=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 HAWSQZCWOQZXHI-UHFFFAOYSA-N 0.000 description 1
GAGWJHPBXLXJQN-UORFTKCHSA-N Capecitabine Chemical compound C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1[C@H]1[C@H](O)[C@H](O)[C@@H](C)O1 GAGWJHPBXLXJQN-UORFTKCHSA-N 0.000 description 1
GAGWJHPBXLXJQN-UHFFFAOYSA-N Capecitabine Natural products C1=C(F)C(NC(=O)OCCCCC)=NC(=O)N1C1C(O)C(O)C(C)O1 GAGWJHPBXLXJQN-UHFFFAOYSA-N 0.000 description 1
201000009030 Carcinoma Diseases 0.000 description 1
QDHHCQZDFGDHMP-UHFFFAOYSA-N Chloramine Chemical compound ClN QDHHCQZDFGDHMP-UHFFFAOYSA-N 0.000 description 1
UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 description 1
UHDGCWIWMRVCDJ-PSQAKQOGSA-N Cytidine Natural products O=C1N=C(N)C=CN1[C@@H]1[C@@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-PSQAKQOGSA-N 0.000 description 1
YTPLMLYBLZKORZ-UHFFFAOYSA-N Divinylene sulfide Natural products C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 1
206010059866 Drug resistance Diseases 0.000 description 1
HTIJFSOGRVMCQR-UHFFFAOYSA-N Epirubicin Natural products COc1cccc2C(=O)c3c(O)c4CC(O)(CC(OC5CC(N)C(=O)C(C)O5)c4c(O)c3C(=O)c12)C(=O)CO HTIJFSOGRVMCQR-UHFFFAOYSA-N 0.000 description 1
229940118465 Isomerase inhibitor Drugs 0.000 description 1
FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
241000406668 Loxodonta cyclotis Species 0.000 description 1
241000699666 Mus <mouse, genus> Species 0.000 description 1
ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 description 1
229930012538 Paclitaxel Natural products 0.000 description 1
244000236658 Paeonia lactiflora Species 0.000 description 1
235000008598 Paeonia lactiflora Nutrition 0.000 description 1
206010034133 Pathogen resistance Diseases 0.000 description 1
108010004729 Phycoerythrin Proteins 0.000 description 1
208000003251 Pruritus Diseases 0.000 description 1
241000700159 Rattus Species 0.000 description 1
241000283984 Rodentia Species 0.000 description 1
206010039491 Sarcoma Diseases 0.000 description 1
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 description 1
IVTVGDXNLFLDRM-HNNXBMFYSA-N Tomudex Chemical compound C=1C=C2NC(C)=NC(=O)C2=CC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)S1 IVTVGDXNLFLDRM-HNNXBMFYSA-N 0.000 description 1
101150071145 Tox4 gene Proteins 0.000 description 1
JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
WHSUQQAOKWCJRE-UHFFFAOYSA-N [Pt]N Chemical compound [Pt]N WHSUQQAOKWCJRE-UHFFFAOYSA-N 0.000 description 1
230000006978 adaptation Effects 0.000 description 1
239000000556 agonist Substances 0.000 description 1
229960000473 altretamine Drugs 0.000 description 1
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
230000001399 anti-metabolic effect Effects 0.000 description 1
238000011394 anticancer treatment Methods 0.000 description 1
239000003908 antipruritic agent Substances 0.000 description 1
208000026900 bile duct neoplasm Diseases 0.000 description 1
229960004117 capecitabine Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229960004562 carboplatin Drugs 0.000 description 1
190000008236 carboplatin Chemical compound 0.000 description 1
210000003169 central nervous system Anatomy 0.000 description 1
201000007455 central nervous system cancer Diseases 0.000 description 1
208000025997 central nervous system neoplasm Diseases 0.000 description 1
239000013043 chemical agent Substances 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
239000011248 coating agent Substances 0.000 description 1
210000001072 colon Anatomy 0.000 description 1
238000002648 combination therapy Methods 0.000 description 1
229960000684 cytarabine Drugs 0.000 description 1
UHDGCWIWMRVCDJ-ZAKLUEHWSA-N cytidine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O1 UHDGCWIWMRVCDJ-ZAKLUEHWSA-N 0.000 description 1
229960003901 dacarbazine Drugs 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
239000012895 dilution Substances 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000000539 dimer Substances 0.000 description 1
VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 description 1
229960003668 docetaxel Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
239000008393 encapsulating agent Substances 0.000 description 1
YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 description 1
229960001904 epirubicin Drugs 0.000 description 1
239000000945 filler Substances 0.000 description 1
239000010200 folin Substances 0.000 description 1
229930182470 glycoside Natural products 0.000 description 1
230000035876 healing Effects 0.000 description 1
210000002767 hepatic artery Anatomy 0.000 description 1
230000002440 hepatic effect Effects 0.000 description 1
UUVWYPNAQBNQJQ-UHFFFAOYSA-N hexamethylmelamine Chemical compound CN(C)C1=NC(N(C)C)=NC(N(C)C)=N1 UUVWYPNAQBNQJQ-UHFFFAOYSA-N 0.000 description 1
229960001101 ifosfamide Drugs 0.000 description 1
239000003978 infusion fluid Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
210000000936 intestine Anatomy 0.000 description 1
238000001361 intraarterial administration Methods 0.000 description 1
230000003834 intracellular effect Effects 0.000 description 1
238000007918 intramuscular administration Methods 0.000 description 1
238000001990 intravenous administration Methods 0.000 description 1
229910052741 iridium Inorganic materials 0.000 description 1
GKOZUEZYRPOHIO-UHFFFAOYSA-N iridium atom Chemical compound [Ir] GKOZUEZYRPOHIO-UHFFFAOYSA-N 0.000 description 1
231100001231 less toxic Toxicity 0.000 description 1
239000007788 liquid Substances 0.000 description 1
230000036210 malignancy Effects 0.000 description 1
230000007246 mechanism Effects 0.000 description 1
229960001924 melphalan Drugs 0.000 description 1
239000002207 metabolite Substances 0.000 description 1
229960000485 methotrexate Drugs 0.000 description 1
229960004857 mitomycin Drugs 0.000 description 1
229960001156 mitoxantrone Drugs 0.000 description 1
KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
230000036457 multidrug resistance Effects 0.000 description 1
210000003205 muscle Anatomy 0.000 description 1
210000001672 ovary Anatomy 0.000 description 1
229960001592 paclitaxel Drugs 0.000 description 1
210000000496 pancreas Anatomy 0.000 description 1
238000007911 parenteral administration Methods 0.000 description 1
JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 1
230000003389 potentiating effect Effects 0.000 description 1
239000000843 powder Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
230000005855 radiation Effects 0.000 description 1
229960004432 raltitrexed Drugs 0.000 description 1
230000008439 repair process Effects 0.000 description 1
238000011160 research Methods 0.000 description 1
230000004044 response Effects 0.000 description 1
230000007017 scission Effects 0.000 description 1
235000015170 shellfish Nutrition 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
239000002904 solvent Substances 0.000 description 1
210000000278 spinal cord Anatomy 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
239000008174 sterile solution Substances 0.000 description 1
210000002784 stomach Anatomy 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
150000008163 sugars Chemical class 0.000 description 1
238000001356 surgical procedure Methods 0.000 description 1
208000024891 symptom Diseases 0.000 description 1
239000006188 syrup Substances 0.000 description 1
235000020357 syrup Nutrition 0.000 description 1
230000009885 systemic effect Effects 0.000 description 1
RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 description 1
229960001278 teniposide Drugs 0.000 description 1
229930192474 thiophene Natural products 0.000 description 1
229960001196 thiotepa Drugs 0.000 description 1
UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 description 1
229960000303 topotecan Drugs 0.000 description 1
238000002054 transplantation Methods 0.000 description 1
238000007492 two-way ANOVA Methods 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
229960003048 vinblastine Drugs 0.000 description 1
JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
229960004528 vincristine Drugs 0.000 description 1
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 1
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 1
GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 description 1
229960002066 vinorelbine Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Gastroenterology & Hepatology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

TW089106805A 1999-04-29 2000-04-12 Synergistic pharmaceutical compositions comprising anthracycline derivatives and anticancer agents TWI222863B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GBGB9909925.1A GB9909925D0 (en)	1999-04-29	1999-04-29	Combined preparations comprising anthracycline derivatives

Publications (1)

Publication Number	Publication Date
TWI222863B true TWI222863B (en)	2004-11-01

Family

ID=10852508

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
TW089106805A TWI222863B (en)	1999-04-29	2000-04-12	Synergistic pharmaceutical compositions comprising anthracycline derivatives and anticancer agents

Country Status (16)

Country	Link
US (2)	US6537990B1 (de)
EP (3)	EP1173187B1 (de)
JP (1)	JP2002543112A (de)
CN (5)	CN1222294C (de)
AR (1)	AR023616A1 (de)
AT (2)	ATE398457T1 (de)
AU (1)	AU4397700A (de)
DE (2)	DE60039260D1 (de)
DK (1)	DK1173187T3 (de)
ES (2)	ES2204572T3 (de)
GB (1)	GB9909925D0 (de)
HK (1)	HK1045462B (de)
MY (1)	MY136610A (de)
PT (1)	PT1173187E (de)
TW (1)	TWI222863B (de)
WO (1)	WO2000066093A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9916882D0 (en) *	1999-07-19	1999-09-22	Pharmacia & Upjohn Spa	Antitumor synergistic composition
GB9920548D0 (en) *	1999-08-31	1999-11-03	Rhone Poulenc Rorer Sa	Treatment of hepatocellular carcinoma
US7829084B2 (en) *	2001-01-17	2010-11-09	Trubion Pharmaceuticals, Inc.	Binding constructs and methods for use thereof
US7754208B2 (en) *	2001-01-17	2010-07-13	Trubion Pharmaceuticals, Inc.	Binding domain-immunoglobulin fusion proteins
US20030133939A1 (en)	2001-01-17	2003-07-17	Genecraft, Inc.	Binding domain-immunoglobulin fusion proteins
IL157443A0 (en) *	2001-03-14	2004-03-28	Bristol Myers Squibb Co	Pharmaceutical compositions for the treatment of cancer including an epothilone analog and a chemotherapeutic agent
US20080075762A1 (en) *	2001-10-03	2008-03-27	Paul Tardi	Compositions for delivery of drug combinations
CA2383259A1 (en)	2002-04-23	2003-10-23	Celator Technologies Inc.	Synergistic compositions
CA2472578A1 (en) *	2002-01-24	2003-07-31	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Anti-cancer combination and use thereof
TWI323662B (en) *	2002-11-15	2010-04-21	Telik Inc	Combination cancer therapy with a gst-activated anticancer compound and another anticancer therapy
US20060264388A1 (en) *	2003-02-26	2006-11-23	Olga Valota	Method for treating liver cancer by intrahepatic administration of nemorubicin
AU2004222527A1 (en) *	2003-03-18	2004-09-30	Pharmacia Italia Spa	Combined therapy comprising nemorubicin and a cyclooxygenase-2-inhibitor
CN100500212C (zh) *	2005-04-06	2009-06-17	山东蓝金生物工程有限公司	一种抗实体肿瘤药物组合物
RU2423381C2 (ru)	2005-07-25	2011-07-10	Трабьон Фармасьютикалз, Инк.	Снижение количества в-клеток с использованием cd37-специфических и cd20-специфических связывающих молекул
US7776832B2 (en) *	2006-04-21	2010-08-17	Gem Pharmaceuticals, Llc	Anticancer treatment with a combination of taxanes and 13-deoxyanthracyclines
NZ573646A (en)	2006-06-12	2012-04-27	Wyeth Llc	Single-chain multivalent binding proteins with effector function
US20090004134A1 (en) *	2006-09-08	2009-01-01	Obeid Michel Sarkis	Kit for treating a health condition by inducing translocation of an erp57 protein to a cellular membrane
US20100104566A1 (en) *	2007-01-29	2010-04-29	Nerviano Medical Sciences S.R.L.	Antitumor combination comprising a morpholinyl anthracycline and an antibody
JP5302300B2 (ja)	2007-05-11	2013-10-02	ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ	アンスラサイクリンの医薬組成物
US20110021517A1 (en) *	2008-02-26	2011-01-27	Nerviano Medical Sciences S.R.L.	Antitumor combination comprising a morpholinyl anthracycline derivative and demethylating agents
RU2531754C2 (ru) *	2008-04-11	2014-10-27	ЭМЕРДЖЕНТ ПРОДАКТ ДИВЕЛОПМЕНТ СИЭТЛ,ЭлЭлСи,US	Связывающееся с cd37 иммунотерапевтическое средство и его комбинация с бифункциональным химиотерапевтическим средством
US8690833B2 (en)	2011-01-31	2014-04-08	Vascular Pathways, Inc.	Intravenous catheter and insertion device with reduced blood spatter
WO2016105499A1 (en)	2014-12-23	2016-06-30	Intellectual Property Associates, Llc	Methods and formulations for transdermal administration
WO2017053469A2 (en)	2015-09-21	2017-03-30	Aptevo Research And Development Llc	Cd3 binding polypeptides
EP3681479B1 (de)	2017-09-15	2024-01-31	Dyve Biosciences, Inc.	Natriumhydrogencarbonat zur verwendung in der behandlung von gicht und verwandten erkrankungen

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4710564A (en) *	1985-01-18	1987-12-01	Microbial Chemistry Research Foundation	Anthracycline compounds
GB2172594B (en)	1985-03-22	1988-06-08	Erba Farmitalia	New morpholino derivatives of daunorubicin and doxorubicin
US5902809A (en) *	1997-07-03	1999-05-11	Paracure, Inc.	Arglabin compounds and therapeutic uses thereof
GB9806324D0 (en)	1998-03-24	1998-05-20	Pharmacia & Upjohn Spa	Antitumour synergetic composition
GB9820012D0 (en)	1998-09-14	1998-11-04	Pharmacia & Upjohn Spa	Use of an anthracycline derivative for the treatment of a liver tumor

1999
- 1999-04-29 GB GBGB9909925.1A patent/GB9909925D0/en not_active Ceased
2000
- 2000-04-04 EP EP00925158A patent/EP1173187B1/de not_active Expired - Lifetime
- 2000-04-04 EP EP03075776A patent/EP1323423B1/de not_active Expired - Lifetime
- 2000-04-04 DK DK00925158T patent/DK1173187T3/da active
- 2000-04-04 JP JP2000614978A patent/JP2002543112A/ja active Pending
- 2000-04-04 DE DE60039260T patent/DE60039260D1/de not_active Expired - Lifetime
- 2000-04-04 DE DE60004348T patent/DE60004348T2/de not_active Expired - Lifetime
- 2000-04-04 HK HK02107029.8A patent/HK1045462B/zh not_active IP Right Cessation
- 2000-04-04 ES ES00925158T patent/ES2204572T3/es not_active Expired - Lifetime
- 2000-04-04 CN CNB008068976A patent/CN1222294C/zh not_active Expired - Fee Related
- 2000-04-04 ES ES03075776T patent/ES2307867T3/es not_active Expired - Lifetime
- 2000-04-04 PT PT00925158T patent/PT1173187E/pt unknown
- 2000-04-04 EP EP08157789A patent/EP1977753A1/de not_active Withdrawn
- 2000-04-04 CN CNA2003101149091A patent/CN1535688A/zh active Pending
- 2000-04-04 AT AT03075776T patent/ATE398457T1/de not_active IP Right Cessation
- 2000-04-04 AU AU43977/00A patent/AU4397700A/en not_active Abandoned
- 2000-04-04 US US09/926,392 patent/US6537990B1/en not_active Expired - Fee Related
- 2000-04-04 WO PCT/EP2000/002923 patent/WO2000066093A2/en not_active Ceased
- 2000-04-04 AT AT00925158T patent/ATE246507T1/de not_active IP Right Cessation
- 2000-04-04 CN CNA2006100597037A patent/CN1853642A/zh active Pending
- 2000-04-04 CN CNA2006100597018A patent/CN1853645A/zh active Pending
- 2000-04-04 CN CNA2003101149119A patent/CN1507869A/zh active Pending
- 2000-04-12 TW TW089106805A patent/TWI222863B/zh not_active IP Right Cessation
- 2000-04-26 MY MYPI20001780A patent/MY136610A/en unknown
- 2000-04-27 AR ARP000101989A patent/AR023616A1/es unknown
2002
- 2002-10-31 US US10/284,144 patent/US6586428B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
CN1535688A (zh)	2004-10-13
AU4397700A (en)	2000-11-17
HK1045462B (zh)	2006-04-28
JP2002543112A (ja)	2002-12-17
US6586428B2 (en)	2003-07-01
ES2307867T3 (es)	2008-12-01
WO2000066093A2 (en)	2000-11-09
DE60004348T2 (de)	2004-02-26
CN1349406A (zh)	2002-05-15
CN1507869A (zh)	2004-06-30
ES2204572T3 (es)	2004-05-01
MY136610A (en)	2008-10-31
DK1173187T3 (da)	2003-10-20
AR023616A1 (es)	2002-09-04
ATE398457T1 (de)	2008-07-15
DE60004348D1 (de)	2003-09-11
CN1222294C (zh)	2005-10-12
EP1977753A1 (de)	2008-10-08
US6537990B1 (en)	2003-03-25
CN1853645A (zh)	2006-11-01
ATE246507T1 (de)	2003-08-15
GB9909925D0 (en)	1999-06-30
HK1045462A1 (en)	2002-11-29
EP1173187B1 (de)	2003-08-06
EP1323423B1 (de)	2008-06-18
DE60039260D1 (de)	2008-07-31
PT1173187E (pt)	2003-10-31
EP1323423A1 (de)	2003-07-02
US20030087839A1 (en)	2003-05-08
CN1853642A (zh)	2006-11-01
EP1173187A2 (de)	2002-01-23
WO2000066093A3 (en)	2001-01-25

Legal Events

Date	Code	Title	Description
2012-08-01	MM4A	Annulment or lapse of patent due to non-payment of fees

Publication	Publication Date	Title
TWI222863B (en)	2004-11-01	Synergistic pharmaceutical compositions comprising anthracycline derivatives and anticancer agents
ES2409755T3 (es)	2013-06-27	Método para Tratar el Cáncer Utilizando un Agente Anticanceroso Combinado
EP3034076B1 (de)	2020-09-30	Kombinierte anwendung einer isothiocyanatverbindung und einer krebsbekämpfenden medizin
EP1272199B1 (de)	2005-01-19	Kombinationstherapien mit gefässschädigender aktivität
US20220265592A1 (en)	2022-08-25	Use of bipolar trans carotenoids with chemotherapy and radiotherapy for treatment of cancer
AU2001242581A1 (en)	2002-01-03	Combination therapies with vascular damaging activity
JP2009536956A (ja)	2009-10-22	抗癌治療法
CN113329772B (zh)	2023-07-18	化学疗法与重组齐整小核菌凝集素的联合疗法
TWI454280B (zh)	2014-10-01	Pharmaceutical composition or combination
US20140127194A1 (en)	2014-05-08	Combined pharmaceutical compositions for the treatment of tumors
JP7311177B2 (ja)	2023-07-19	Ａ－ＮＯＲ－５αアンドロスタン薬物と抗がん薬物との併用
KR101964169B1 (ko)	2019-04-01	항종양성 백금 착체를 함유하는 항종양제 및 항종양 효과 증강제
RU2471496C1 (ru)	2013-01-10	Средства, повышающие противоопухолевую и антиметастатическую активность цитостатических препаратов
CN115869316A (zh)	2023-03-31	伊斯平斯在制备联合抗乳腺癌药物方面的用途
CN106668061B (zh)	2019-04-30	一种含有顺铂的抗癌药物组合物
CN103826645A (zh)	2014-05-28	砷在癌症治疗保护中的用途
Baghli	2024	Targeting the Mitochondrial-Stem Cell Connection in Cancer Treatment: A Hybrid Orthomolecular
RU2268729C2 (ru)	2006-01-27	Комбинированные терапии с использованием активности, повреждающей сосуды
Pratesi et al.	1989	Effects of Tauromustine, a Water-Soluble Nitrosourea Compound, on NMU-1 Murine Lung Tumor
HK40060452A (en)	2022-05-20	COMBINED USE OF A-NOR-5α ANDROSTANE COMPOUND DRUG AND ANTICANCER DRUG
Ernst	2016	Radiotherapy plus heat shock protein 90 inhibition: sensitizing cancer cells to irradiation-induced cell death and enhancing their immunogenicity
WO2018221735A1 (ja)	2018-12-06	新規オリゴヌクレオチド
ZA200207114B (en)	2004-02-04	Combination therapies with vascular damaging activity.
CN101850106A (zh)	2010-10-06	南瓜蛋白在制备治疗胰腺癌药物中的应用